About Alentis Therapeutics
The Claudin-1 Company
Alentis is the leading biotech company developing anti-Claudin-1 therapies. Claudin-1 is an extraordinary target that plays a key role in many solid tumors and fibrosis. We are committed to unlocking the broad potential of Claudin-1 and bringing much-needed new medicines to patients.
Our mission: Treating cancer and reversing fibrosis
We are rapidly advancing a pipeline of first-in-class monoclonal antibodies (mAbs) and antibody-drug conjugates (ADCs) that specifically bind exposed CLDN1 in tumors and fibrotic tissue. By targeting Claudin-1, we aim to address the unmet medical needs of patients suffering from Claudin-1 positive solid tumors and organ fibrosis.
Building on 15 years of research
Alentis Therapeutics was founded in 2019 by Professor Thomas Baumert, after more than 15 years of research and the discovery of an anti-Claudin-1 antibody with his teams at the University of Strasbourg and Inserm. Since its launch, Alentis has grown to a team of over 50 employees developing a clinical-stage pipeline of multiple investigational medicines.
Our founder: Professor Thomas Baumert
Dr. Baumert is a physician-scientist who pioneered Claudin-1 research. In 2023, he was honored with the prestigious INSERM Research Prize for advancing the understanding of fibrosis and cancer.